||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Oxford Biomedica Share Discussion Threads
Showing 96726 to 96748 of 96750 messages
|Chart is approaching support, should see a bounce soon.|
|spivvy algo then :o)|
|This is what Zacks say about themselves. Note 2 explains that it is all mathematical. They presumably have some sort of system that compares a few key facts and auto extrapolates from there. If I looked at 4 or 5 existing facts about OXB, I would probably conclude I should get out fast, too!
Our Analyst Recommendations
Zacks Equity Analysts issue recommendations and target prices for each company in their coverage universe based on a six-month time horizon. These are known as the "Zacks Recommendations" and unlike the Zacks Rank, are ranked by a three-point scale:
Outperform Recommendations: We expect these stocks to outperform the broad market indexes over the next six months.
Neutral Recommendations: We expect these stocks to perform in line with the broad market indexes over the next six months.
Underperform Recommendations: We expect these stocks to under-perform the broad market indexes over the next six-months.
What is the Difference Between the Zacks Recommendation and Zacks Rank?
This is the most frequently asked question about Zacks Equity Research. This can be explained on a couple of levels.
1) What is the Purpose of Each Rating?
The Zacks Rank is a short-term indicator of stock performance that is effective for one to three months. The Zacks Recommendation is meant to be a longer-term rating of 6+ months. Each provides valuable insights into the future profitability of a stock and can be used separately or in combination with each other depending on your investment style.
2) How are they created?
The Zacks Rank is purely mathematical. The rank is produced through a daily quantitative process that looks at four factors dealing with earnings estimate revisions and earnings surprises. The ratings are not determined by Wall Street or some agenda, but a powerful timeliness indicator proving effective in predicting stock price movements relative to the market over the next one to three months.(Learn more about the Zacks Rank.)
Zacks Recommendation is our second quantitative model that gives you long-term guidance to stock picking. This stock-rating system is still rooted in earnings estimates and starts with the Zacks Rank, but you also get insight and fresh recommendations from a team of stock analysts who follow industries, talk to company management and more.
The best way to judge the value of the Zacks Recommendation is through performance. On the following page we provide you insight into the performance of both our Outperform and Underperform recommendations versus the S&P 500. We also break it down our recommendations by industry to show our expertise in each field. View Zacks Equity Research Performance.
Learn more about the difference between these two powerful stock ratings systems.|
|I'm probably being over optimistic, but the half-full part of my glass was sort of hoping that the FDA would have made the decision on CTL019 in ALL before that mid-June presentation on DLBCL.|
harry s truman
|Novartis said it will continue to aggressively strengthen its internal pipeline with early stage acquisitions and in-licensing deals.
I agree re Trovax Doc, pity someone would not take it and use combinations.
I wonder will NVS consider OXB?
Novartis said it will continue to aggressively strengthen its internal pipeline with early stage acquisitions and in-licensing deals.
Novartis noted that the price of assets has gone up in the sector so it is going ‘upstream', or into earlier stage assets to find value. Novartis typically focuses on assets in the $2-5 billion range. This is notable because M&A is inherently important in the biotech industry where the biggest players are flush with cash and hungry for growth with serious business development initiatives.
Yet, all attention has turned to its breakout immuno-oncology pipeline, particularly in CAR-T.
The company expects its closely watched CAR-T therapy, which is currently undergoing review in the U.S., to "be big business in oncology," said Jimenez|
|I hadn't heard of zacks until today. I couldn't find anything substantial but the recent trading activity does seem odd considering things look better than they ever have.|
|I'm thinking Zacks is just some spivvy algo system, or do they have real, half decent analysts??|
|Well according to the ADVFN app there has been 0 buy trades today.Very odd.|
|DLBCL is a NHL. KTE-C19 is the direct competitor to CTL019. It will be an interesting comparison!|
|Kite is on straight after for NHL.
15:40 007 GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN
ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE BCELL
LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS
S.J. Schuster, Philadelphia, PA (USA)
15:55 008 AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH
REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMAS (NHL): PRIMARY
RESULTS OF THE PIVOTAL TRIAL ZUMA-1
S.S. Neelapu, Houston, TX (USA)|
|14th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA
Wednesday, June 14, 2017, 15:40
GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE BCELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS S.J. Schuster, Philadelphia, PA (USA)
|Finally! Novartis AG (NVS) to Release Long-Awaited Juliet CAR-T Data in June
4/25/2017 6:28:40 AM
Jefferies analyst Biren Amin said last night that he thought Novartis would be presenting its midstage CAR-T blood cancer data from Juliet at a Swiss conference in mid-June, the Big Pharma has confirmed to FierceBiotech that it will indeed be posting the long-awaited data.
In a note to clients posted last night, Amin said that: “Titles released for the International Conference on Malignant Lymphoma (ICML) indicate that Novartis intends to present the interim look from the phase 2 Juliet trial in DLBCL [diffuse large B-cell lymphoma].”
The Juliet data have already been seen by Novartis and the FDA, with the midstage test assessing its cutting-edge CAR-T med tisagenlecleucel (a.k.a. CTL019) in DLBCL patients–a key battle ground with rival biotech Kite Pharma and its axicabtagene ciloleucel (a.k.a. KTE-C19), as both race to be first to market.|
|Interesting, I always thought it was a sheet like cancer that grew on the lung surface as a single cell layer progressively covering the area when the patient would eventually suffer asphixiation. Possibly the primary site is elsewhere and it invades the lung surface?
I have not read up on this matter and maybe entirely incorrect.
Sorry to hear about your friend.|
|Spelling?...I should check that. I meant selling.|
|#23554Hi Pram,Google Finance has the Zacks downgrade report dated as 31 Mar so possibly old news.Not sure what the spellings about though.|
|Hmm. Zacks may be the reason for some selling. Has anyone read the report, I can only see their 'somewhat gory' heading ("get out quick!).|
That being said, if CAR T-cell therapy can cure a third of patients with refractory DLBCL, why not use it earlier? These agents could move toward the frontline setting
Zacks Investment Research Lowers Oxford Biomedica (OXBDF) to Sell
April 3rd, 2017 • 0 co
|Novartis results out.
Basel, April 25, 2017 — Commenting on the results, Joseph Jimenez, CEO of Novartis, said:
“Novartis delivered another solid performance in the first quarter. Growth drivers, including Cosentyx and Entresto, more than offset generic erosion, mainly due to Glivec. The innovation momentum continued in the quarter, led by the launch of Kisqali, and the FDA Priority Review for CTL019 in the US. This reinforces our confidence in our next growth phase, which we expect to start in 2018.”|
|It is truly baffling Harry. That said, I would speculate that we have now retraced to a level where I would expect a bit of support and a possible push back up just because of the buying opportunity now presentedI can't see any reason at all for the drop based on current knowns...even with the debt.|
|To me there is plainly a seller out there at the moment, which begs the question of who holds for all of this time and then sells when we're expecting a decision from the FDA which would materially change the future prospects of the company if affirmative?
I don't have an answer to that question.
However, and without wanting to curse you with my praise, I feel that a sub 5p purchase today has an excellent chance of being 2 or 3 times that by the end of the year if the decision goes as expected. Has to be worth the risk of the downside.
I'm very tempted myself, but as mentioned previously I already have enough. Too many really. If it carries on like this though, I might succumb. All it needs is for the FDA to say yes (and I think even doc has that down as an 8/10 chance at this point) and OXB have big manufacturing income for the near future.|
harry s truman
As I understand it, mesothelioma is by its nature inoperable, as it is the 'bag' which surrounds the lungs that is the seat of the cancerous cells.|
|Seems to be slipping a bit, now only fractionally above 4.5p.|
|I've taken this dip under 5p to add. Now my largest share holding in my SIPP.|